Celldex has announced positive results from two phase 3 trials of its monoclonal antibody in patients with chronic spontaneous urticaria, a chronic skin condition. According to Fierce Biotech, the company touted the outcome as a double win in patients whose disease had not responded to existing treatment.
The results are notable because they represent a rebound for the antibody program, suggesting the therapy had faced questions or setbacks before these data. The trial population being treatment-refractory adds significance, as these patients typically have limited options.
With two successful phase 3 studies, Celldex appears to have strengthened the case for advancing the therapy. Further details on safety and efficacy will be important, but the announcement marks a clear turning point for the asset.